March 2, 2011 — An updated guideline on the use of bone-modifying agents in patients with metastatic breast cancer have been issued by the American Society of Clinical Oncology (ASCO). The guideline ...

Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice The following represents disclosure information provided by authors of this ...

Despite guidelines recommending bone-modifying agents (BMAs) to decrease skeletal-related events (SREs) in men with metastatic castration-resistant prostate cancer (mCRPC), BMAs are underutilized. In ...

The American Society of Clinical Oncology first published evidence-based practice guidelines for the use of bisphosphonates in breast cancer in 2000 and updated them in 2003. To reflect the proven ...

Bisphosphonates are popular bone-targeting drugs. Older people take them to prevent and treat osteoporosis. Breast cancer patients, particularly those with metastatic disease, take them to prevent and ...

Denosumab, a bone-modifying agent for cancer treatment, is being overused and costing Medicare more than $43 million each year, a recent Memorial Sloan Kettering study found. The study, published in ...

Xgeva (denosumab) is a prescription drug that’s used to treat some kinds of cancer. Xgeva comes as a solution inside prefilled, disposable pens that’s injected under the skin. It’s usually given once ...

The management of bone lesions from advanced solid tumors and multiple myeloma typically includes use of a bone-modifying agent to reduce the risk of skeletal-related events. Recent data demonstrate ...